6533b7dbfe1ef96bd1271436

RESEARCH PRODUCT

Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure.

subject

description

/ T cells responding to HIV-1 peptides were observed in none of 11 HIV- seronegative donors without a history of HIV exposure. ELISPOT assays are relatively fast and easy to perform and appear to reliably detect T cell reactivity due to previous exposure to HIV. These findings support the use of the ELISPOT assay for monitoring T cell responsiveness to HIV peptides. In acute infection with the human immunodeficiency virus We described recently an enzyme-linked immunospot (ELISPOT) assay to detect and quantitate single blood-de- type 1 (HIV-1), initial reduction in virus load is associated with the appearance of a high frequency of antiviral cytotoxic T rived CD8 / T lymphocytes forming tumor necrosis factor (TNF)-a spots after contact with peptide-loaded target cells lymphocytes (CTL) that usually remain detectable in peripheral blood during the entire asymptomatic phase of the disease (1). in vitro (7). The number and area of resulting cytokine spots were automatically determined with the use of computer-as-